- We welcome research from across the entire field of retroviruses, supporting the research community with a progressive and inclusive approach.
- Ranked among the top virology journals worldwide, we publish high quality research and expert reviews across basic science, translational, and clinical research.
- Our expert and highly responsive team of Editors provides excellent service throughout, with rapid evaluation and publication of research with broad and lasting impact.
- Founded in 2004, we are one of the leading influencers in HIV/AIDS and retrovirus research, reaching a large global audience.
Aims and scope
Retrovirology is an open access, online journal that publishes stringently peer-reviewed, high-impact articles on host-pathogen interactions, fundamental mechanisms of replication, immune defences, animal models, and clinical science relating to retroviruses. Retroviruses are pleiotropically found in animals. Well-described examples include avian, murine and primate retroviruses. Two human retroviruses are especially important pathogens. These are the human immunodeficiency virus, HIV, and the human T-cell leukemia virus, HTLV. HIV causes AIDS while HTLV-1 is the etiological agent for adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology aims to cover comprehensively all aspects of human and animal retrovirus research.
Why publish your article in Retrovirology?
Retrovirology is an affiliated journal of the following academic societies (members are eligible for a 15% discount on the article-processing charge):
Eligibility: Society members should contact their society and request the submission code. Upon submission to the journal, authors should request a waiver at the “APC Agreement” stage of submission and quote the submission code (text box provided).
All articles published by Retrovirology are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Retrovirology you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BMC license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BMC can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Retrovirology therefore levies an article-processing charge of £1990.00/$2890.00/€2390.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
Visit Springer Nature’s open access funding & support services for information about research funders and institutions that provide funding for APCs.
Springer Nature offers agreements that enable institutions to cover open access publishing costs. Learn more about our open access agreements to check your eligibility and discover whether this journal is included.
For more information on APCs please see our Journal Pricing FAQs
All articles published in Retrovirology are included in:
- Biological Abstracts
- Current contents
- Global Health
- PubMed Central
- Science Citation Index
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Peer-review is the system used to assess the quality of a manuscript before it is published. Independent researchers in the relevant research area assess submitted manuscripts for originality, validity and significance to help editors determine whether the manuscript should be published in their journal. You can read more about the peer-review process here.
Retrovirology operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
Submitted manuscripts will generally be reviewed by two or more experts who will be asked to evaluate whether the manuscript is scientifically sound and coherent, whether it duplicates already published work, and whether or not the manuscript is sufficiently clear for publication. The Editors will reach a decision based on these reports and, where necessary, they will consult with members of the Editorial Board.
All manuscripts submitted to Retrovirology should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Retrovirology
Articles in Retrovirology should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Retrovirology [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Retrovirology 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
Benefits of publishing with BMC
Retrovirology's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Retrovirology offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Retrovirology gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Retrovirology are included in article alerts and regular email updates. Some may be highlighted on Retrovirology’s pages and on the BMC homepage.
In addition, articles published in Retrovirology may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Retrovirology. A list of articles recently press-released by journals published by BMC is available here.
As an author of an article published in Retrovirology you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BMC license agreement).
For further information about the advantages of publishing in a journal from BMC, please click here.
Annual Journal Metrics
42 days to first decision for reviewed manuscripts only
35 days to first decision for all manuscripts
116 days from submission to acceptance
13 days from acceptance to publication
264 Altmetric mentions